In a significant advancement for patients battling multiple myeloma, the U.S. Food and Drug Administration (FDA) has granted approval to a combination therapy featuring teclistamab and daratumumab hyaluronidase-fihj. This approval, announced on March 5, 2026, offers a new treatment option for adults with relapsed or refractory multiple myeloma who have already undergone at least one prior line of therapy. The decision marks a milestone in the agency’s efforts to expedite the availability of innovative therapies for challenging-to-treat cancers.
Multiple myeloma, a cancer of plasma cells, remains a difficult disease to manage, often relapsing after initial treatment. This new combination, marketed as Tec-Dara, provides a much-needed alternative for patients whose disease has returned or develop into resistant to standard treatments. The FDA proactively awarded a voucher for the drug combination on December 15, 2025, recognizing the promising results demonstrated in a Phase 3 clinical trial. This proactive approach underscores the agency’s commitment to accelerating access to potentially life-saving medications.
Breakthrough Trial Results Drive Approval
The approval is based on data from the MajesTEC-3 clinical trial (NCT05083169), a randomized study involving 587 patients. Participants were assigned to receive either the teclistamab and daratumumab hyaluronidase combination or a control group receiving daratumumab hyaluronidase, pomalidomide, and dexamethasone (DPd) or daratumumab hyaluronidase, bortezomib, and dexamethasone (DVd). The trial demonstrated a substantial improvement in progression-free survival for those receiving the combination therapy. Specifically, the risk of disease progression or death was reduced by 83% relative to the standard of care control arm, according to the FDA. FDA Press Release
Median progression-free survival was not reached in the teclistamab and daratumumab hyaluronidase arm, while it was 18.1 months (95% confidence interval = 14.6–22.8) in the control arm (hazard ratio = 0.17, 95% CI = 0.12–0.23; P < .0001). Median overall survival was also not reached in either arm (hazard ratio = 0.46, 95% CI = 0.32–0.66), indicating a potential benefit in long-term survival. ASCO Post
National Priority Voucher Program Speeds Access
This approval is the third under the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program. The CNPV program aims to expedite the review of applications for drugs that address critical national health priorities, including unmet medical needs and innovative therapies. The program offers incentives to pharmaceutical companies to prioritize the development of treatments for serious conditions. “The FDA is now proactively moving to cut idle time to accelerate meaningful treatments for the American people,” stated FDA Commissioner Marty Makary, M.D., M.P.H. FDA Press Release
The combination therapy is approved for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval also converts the 2022 accelerated approval for teclistamab as a single agent (monotherapy) to a traditional approval. This monotherapy indication is for patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Cure Today
What’s Next for Multiple Myeloma Treatment?
The approval of Tec-Dara represents a significant step forward in the treatment of relapsed or refractory multiple myeloma. Researchers will continue to monitor the long-term effects of the combination therapy and explore its potential in earlier lines of treatment. Further studies are also underway to identify biomarkers that may predict which patients are most likely to benefit from this innovative approach. The FDA’s proactive voucher program and commitment to accelerating drug approvals signal a continued focus on bringing effective treatments to patients in require.
Have you or a loved one been affected by multiple myeloma? Share your thoughts and experiences in the comments below. Please also share this article with anyone who might find this information helpful.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
